After the wildfire: how will healthcare recover from the pandemic?
Following a forest fire, the natural world recovers according to predictable patterns, in a process known as ‘ecological succession’. After the global conflagration of COVID-19, what will the equivalent patterns look like for health?
Apollo’s 2022 Healthcare Predictions
Every year we ask our proprietary panel of physicians to share their perspectives on the healthcare industry for the coming year. Amid continued pandemic-related disruption, this year’s global insights will share provider views on the last year, thoughts on coming change in the industry, and their hopes for 2022.
AllPayor Contract Negotiation & Pricing Transparency
On July 19, 2021, the Centers for Medicare and Medicaid Services (CMS), as part of proposed rule covering a variety of subjects, including Medicare Hospital Outpatient and Ambulatory Surgery Center PPS modifications, issued a proposed rule with an opportunity to comment (the Rule) amending the hospital price transparency regulations. (The Rule is scheduled to be published in the Federal Register on August 4, 2021.) The Rule seeks to modify the existing hospital price transparency regulations codified at 45 C.F.R. part 180 Subpart C. View what may be considered the finest Contract Negotiation & Pricing Transparency Module (Patient Quote) available for Increased Productivity & Reimbursement for Hospitals & Physician Groups
Bridging the HCEI Divide – Insights on an Effective Healthcare Economic Information (HCEI) Exchange
While the FDA has set guidelines on proactive manufacturer communications of healthcare economic information (HCEI) to payers, there still appears to be a gap between what payers are asking for and what manufacturers are providing. So why the gap, and how might this be impacting payer decision making? And what might prove helpful for manufacturers to enhance this exchange? Join our panel for research findings and insights into these critical questions, along with strategies to close the gap.
Global Medicines Outlook to 2026
Join us for a moderated panel discussion with IQVIA leaders following the release of a recent IQVIA Institute report on The Global Use of Medicines 2022.
Getting real with real-world evidence: A discussion on building successful programs
Join this webinar to hear from regulatory affairs professionals, pharmaceutical company executives and leaders in data and AI as they discuss the challenges and opportunities for RWE across the drug lifecycle and lessons learned building successful RWE analytics programs.
Improving Performance: Selection and Development of PerfO Assessments to Capture Clinical Benefit: Performance Outcome Assessment Emerging Good Practices Task Force
This webinar will be useful for researchers, regulators, academics, industry sponsors, and instrument developers in the clinical outcomes assessment (COA) field working on the development, evaluation, and implementation of performance outcome (PerfO) measures for use in capturing clinical benefits in treatment trials for medical label claims. Speakers will present work to date and invite audience feedback on several areas where there is a lack of consensus.
Digital Transformation to Support Operational, Therapeutic and Clinical Decision Making
As the industry faces significant staff shortages, the implementation of automation becomes all the more critical for ensuring patients can continue to receive the care that they need. We must pivot our approach now, fully embrace the automation of menial clinician and administrative tasks and relieve our overstretched staff of these unnecessary burdens.
Novel co-creation for novel trial design: How co-creation differs within DCTs and traditional trials
The question of patient co-creation in clinical has moved far beyond the why and into the how. After a pandemic-driven explosion of trial design innovation, widespread adoption of DCT and Hybrid trials has accelerated, driving with it a plethora of new patient preference insights.
Biosimilars’ Key Next Steps: What Will the Future Bring?
This webinar emerges in the sequence of relevant topics highlighted in the ISPOR Science Strategy (particularly the Special Populations and Technologies and Health Economics, Access and Policy sections) and the Special Interest Group on biosimilars, by specifically reflecting on how to tackle inefficiencies of healthcare systems in the future with biosimilars. The session takes a global perspective on the future of biosimilars, and presents an insightful exchange of views from experts from various regions worldwide.
Webinar: Busting the 5 Myths of Data Sharing in Healthcare
Although sharing data securely is a mission-critical capability for healthcare providers, it is an elusive step in driving true interoperability. With exploding health data volumes and the pressure to inform patient outcomes and experiences with data-driven insights, healthcare providers need unfettered and governed access to valuable data sources within and outside of their organization.
The Guide to Patient Involvement in Rare Disease Therapy Development
On January 27th, the EveryLife Foundation for Rare Diseases, in partnership with Biotechnology Innovation Organization (BIO), National Health Council, and the Pharmaceutical Research and Manufacturers of America (PhRMA), will introduce a transformational resource, the “Guide to Patient Involvement in Rare Disease Therapy Development.”
Using RWE to Accelerate Market Access in Rare Diseases
This unique training focuses on leveraging patient-centric Real-World Evidence (RWE) to accelerate the patient and market access of innovative and potentially transformative Orphan Medicinal Products (OMPs). Delegates will address the challenge of early market access based on fewer and less mature data, with the creation of an Early Value Proposition and a Patient-Centric Evidence Generation Plan that comprehensively support value demonstration, product positioning, and that meets stakeholders’ requirements.
Digital Transformation to Support Operational, Therapeutic and Clinical Decision Making
As the industry faces significant staff shortages, the implementation of automation becomes all the more critical for ensuring patients can continue to receive the care that they need. We must pivot our approach now, fully embrace the automation of menial clinician and administrative tasks and relieve our overstretched staff of these unnecessary burden
The new one in the German Ministry of Health? All the same or significant changes?
On September 26 2021 the German population voted for a change in politics. In December 2021 the new government started their work including Prof. Dr. Karl Lauterbach as their new Ministry of Health. What does this change potentially mean to the pharmaceutical industry especially for market access?
Presenting Chris Deacon…Unplugged
Chris Deacon is going to give us the inside scoop on the successes and challenges in managing the highest-visibility health benefit in the country north of Bentonville...and what she learned and we can learn from her experience.
Cutting Edge Conversations
Join our upcoming virtual discussions that offer a deep-dive into specific research areas. Each meeting will focus on a specific challenge and showcase the innovative approaches of different research organizations. During the live Q&A session all attendees will participate in lively discussion on the given problem and solutions. We hope to see you there!
How to improve Net Pricing in Tenders & Contracts
The EPP live-interactive learning programs, to improve your pricing knowledge with high quality content, develop new skills and meet international pricing peers all in the comfort of your own home/office.
Get ready to self-disrupt: Embed actionable insights to pioneer a connected customer experience
Reuters Events: Pharma USA 2022 (March 16-17, 2022, Philadelphia – formerly eyeforpharma Philadelphia) is where 1,000+ pharma leaders and critical stakeholders will unite to draw the blueprints and construct frameworks for the future of our industry. Prioritize customer journeys over brand journeys, commit to a people-driven, tech-enabled transformation and inject data into every decision made to realize innovation that transforms lives.
ISPOR 2022
Join global healthcare leaders, in-person and virtually, as they convene at ISPOR 2022, the leading global conference for Health Economics and Outcomes Research (HEOR), May 15-18, for discussion and dissemination of the latest trends in healthcare. This must-attend event provides you with dedicated opportunities to network in-person and virtually with your peers, HEOR experts, and thought leaders and to discuss with a global audience how we establish, incentivize, and share value sustainable for health systems, patients, and technology developers.
Signal Series
Signal—ISPOR’s new signature program—looks beyond today’s linear thinking to explore topics that will shape healthcare decision making over the next decade. Seeking to strengthen strategic foresight and adaptive leadership capacities in the complex world of healthcare, the Signal series focuses on the “big picture,” while also addressing how health economics and outcomes research (HEOR) can best contribute to solving healthcare’s greatest challenges.
ISMPP U: RWE Communication Challenges – Building Acceptance Through Transparency, Stakeholder Outreach and Health System Adoption
This webinar will educate on the opportunities and challenges of using Real World Evidence (RWE) in medical communications and publication planning. Multiple stakeholder perspectives including that of publication professionals, journal editors, RWE writers and consultants will be discussed.
Enabling “Direct to Consumer” Clinical Trials with Innovative Digital Platforms: A Case Study – Hearts of Athletes and COVID-19
In this webinar, learn how the Duke Heart Center launched a fully digital, decentralized clinical study leveraging Deloitte’s ConvergeHEALTH MyPath for Clinical platform powered by Amazon Web Services (AWS) to study the impact of COVID-19 on athletes’ heart health. Discover how this important study could give us insights into the impact of COVID on elite athletes, as well as the role that cloud based digital platforms can play to accelerate recruitment and improve retention and event ascertainment to augment the in-person visits that would have been required in the past.